ClinicalTrials.gg
Active, not recruitingNCT03539575CB1R in SpiceUpdated Apr 29, 2026

CB1R in Synthetic Psychoactive Cannabinoids

An interventional study of [11-C]OMAR in Drug Dependence, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Yale University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Substance-Related Disorders by Yale University — 6 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · Yale University.

Planned enrollment
51st of 59
15 · median 74
Started
2018
with 5 others
No phase
32 of 63
4 open now
Registered
41st of 63
by date

Among the 63 studies in Substance-Related Disorders by Yale University, this one is the 51st largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2018, is one of 32 with no phase, and was the 41st registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

6 of the 63 studies in Substance-Related Disorders by Yale University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Substance-Related Disorders by Yale University, or all of them as a file.
02

Study summary

The purpose of this research study is to determine whether the CB1R availability is lower in synthetic psychoactive cannabinoid subjects using the most widely available synthetic psychoactive cannabinoids at the time the study is initiated.

03

Conditions studied

  • Drug Dependence

Keywords

  • K2
  • Spice
  • Synthetic Marijuana
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written consent
  • Age 18-55
  • Current Synthetic Psychoactive Cannabinoids consumption

Exclusion criteria

Exclusion:

  • MRI metal exclusions and claustrophobia
  • Education completed is less than 12 years
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    Synthetic Psychoactive Cannabinoid Users

    Synthetic Psychoactive Cannabinoid dependent subjects who are frequent spice/K2 users will receive the radiotracer \[11-C\]OMAR.

    Other: [11-C]OMAR

Interventions

  • Other[11-C]OMAR

    The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

06

What researchers measure

Primary outcomes

  1. Positron Emission Tomography (PET Imaging)

    CB1R availability using \[11-C\]OMAR PET imaging Change in CB1R availability (e.g. volume distribution).

    Time frame: Change in CB1R availability from baseline throughout one test day

Secondary outcomes

  1. CogState Battery

    2\. Changes in Cognition during withdrawal using a computerized battery Changes in cognitive functions such as attention, memory, motor functioning, and processing speed.

    Time frame: Change in CB1R availability from baseline throughout one test day

  2. Electroencephalogram

    3\. Changes in brain rhythms measured by Electroencephalography Changes in electroencephalographic (EEG) brain rhythms related to information processing.

    Time frame: Change in CB1R availability from baseline throughout one test day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Dec 2026, 103 months after the start.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 103 months is above that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
May 29, 2018
StartActual
May 1, 2018
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03539575
Lead sponsor
Yale University
Responsible party
Deepak C. D'Souza (Professor of Psychiatry, Yale University) — Principal investigator
First posted
May 29, 2018
Start date
May 1, 2018
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Deepak C D'Souza, M.D.
principal investigator · Yale University
Mohini Ranganathan, M.D.
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion